We focused on MRD detection by IG/TR analysis in ALL patients; MRD analysis using BCR::ABL1 fusion gene transcripts is clearly different and requires specific guidelines and QA schemes [9], whereas MRD detection in lymphoma patients also has several differences compared to ALL (presence of somatic hypermutations, absence of clonal evolution, focus on fusion genes, and a low degree of tumor infiltration at diagnosis, hampering the generation of a standard curve and thereby favoring analysis by ddPCR) [10]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.